Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06146322 · ClinicalTrials.gov registry record · NA
Barley Beta-glucan, Glycemic Control, and Appetite
A NA study of Diabetes and Diet, Healthy, sponsored by Washington State University.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT06146322: Completed NA study of Diabetes and Diet, Healthy, sponsored by Washington State University.
NCT06146322 is a NA study of Diabetes and Diet, Healthy that has completed, run by Washington State University. The registered enrollment target is 16 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06146322, a NA study of Diabetes and Diet, Healthy, has completed, sponsored by Washington State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
Novel barley varieties high in the soluble fiber β-glucan have the capacity to improve population health through improving glycemic control. Sweetened and unsweetened wholegrain barley foods were tested in a randomized, controlled, crossover human clinical trial to assess impact on postprandial appetite and food intake.
Primary Outcome
Blood glucose measured every 15 minutes post-preload ingestion
Conditions Studied
Interventions
- OTHER WR
- OTHER LB
- OTHER MB
- OTHER HB
- OTHER WR+50g HFCS
Study Locations (1)
Washington
- Washington State University - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2020-10-31 |
| Phase | NA |
What the finished NCT06146322 record still lists
NCT06146322 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower).
The record links to 5 conditions, with Diabetes appearing as the primary indexed condition, and to 5 interventions - of which WR is the first listed.
NCT06146322 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06146322 about?
NCT06146322 is a clinical study titled "Barley Beta-glucan, Glycemic Control, and Appetite". Novel barley varieties high in the soluble fiber β-glucan have the capacity to improve population health through improving glycemic control. Sweetened and unsweetened wholegrain barley foods were tested in a randomized, controlled, crossover human clinical trial to assess impact on postprandial appe...
What is the current status of trial NCT06146322?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2019-10-01. Estimated completion is 2020-10-31.
What conditions does trial NCT06146322 study?
This clinical trial studies the following conditions: Diabetes, Diet, Healthy, Appetitive Behavior, Blood Sugar; High, Appetite and General Nutritional Disorders.
What interventions are being tested in trial NCT06146322?
The interventions under investigation include: WR (OTHER), LB (OTHER), MB (OTHER), HB (OTHER), WR+50g HFCS (OTHER).
Who is sponsoring clinical trial NCT06146322?
This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06146322 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06146322's enrollment target sits among peer trials
16 319th of 338 higher than 17 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Bringing Advocacy Via Digital Guide to the Emergency Department (Project BADGE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI